Redburn Atlantic analyst Jamie Clark initiated coverage of Lonza (LZAGY) with a Buy rating and CHF 650 price target Lonza, as the world’s largest contract development and manufacturing organization, has long-term contracted revenues and high barriers to entry, while demand for biologic capacity is booming, the analyst tells investors. The firm sees the material investment Lonza has made in expanding its capacity between 2024 and 2026 driving high-teens biologics revenue growth and a 2024-27 core EPS compound annual growth rate of 19% with additional long-term upside catalysts, the analyst added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LZAGY: